This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is McKesson (MCK) a Great Stock for Value Investors?
by Zacks Equity Research
Let???s see if McKesson (MCK) stock is a good choice for value-oriented investors right now from multiple angles.
Rite Aid (RAD) Stock Up on Q3 Earnings Beat, FY19 View Down
by Zacks Equity Research
Rite Aid's (RAD) top and bottom lines improve year over year. Also, earnings came ahead of the Zacks Consensus Estimate but sales lagged the same.
Is McKesson (MCK) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
BD Brings HealthSight Diversion App to Combat Opioid Crisis
by Zacks Equity Research
BD's (BDX) latest development is likely to boost the company's Medication Management unit.
McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates
by Zacks Equity Research
McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.
McKesson (MCK) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 9.76% and -0.90%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Earnings Lineup for Oct 25: SYK, CERN & More
by Zacks Equity Research
Long-term potential of the Medical Products industry looks promising at the moment amid certain short-term geopolitical insecurities.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q3 Earnings?
by Zacks Equity Research
PerkinElmer (PKI) likely to gain from strong segmental revenues in Q3; a raised earnings guidance for 2018 is promising.
Can Medication Delivery Unit Aid Baxter's (BAX) Q3 Earnings?
by Zacks Equity Research
Baxter (BAX) likely to gain from strong Medication Delivery revenues; guidance for 2018 raised.
Will Core MedSurg Segment Aid Stryker's (SYK) Q3 Earnings?
by Zacks Equity Research
Stryker (SYK) is likely to gain from strong segmental performance in Q3; softness anticipated in Spine business.
Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?
by Zacks Equity Research
McKesson (MCK) is expected to gain from strong segmental performances in Q2 of fiscal 2019.
McKesson (MCK) Q2 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Allscripts (MDRX) Stock Now
by Zacks Equity Research
Strong prospects in Sunrise EHR platform to aid Allscripts (MDRX). However, intense competition in the MedTech space is a headwind.
NextGen Rides on Prospects in RCM Space, Competition Rife
by Zacks Equity Research
NextGen (NXGN) is a major player in the U.S. RCM market. However, the company faces cutthroat competition in the healthcare information systems and services market.
Quality Systems Ties Up With CoverMyMeds to Enable ePA
by Zacks Equity Research
Quality Systems' (QSII) new collaboration with CoverMyMeds sees bright market prospects.
Cerner (CERN) Strong on EHR Prospects, Competition Intense
by Zacks Equity Research
Cerner's (CERN) strong EHR prospects and global outlook aid the company; margins continue to decline.
Cardinal Health Product Spectrum Broad, Competition Rife
by Zacks Equity Research
Cardinal Health's (CAH) strategic buyouts lend it a competitive edge; the Cordis unit lacks luster.
Allscripts' Payerpath & ePrescribe Receive EHNAC Accreditation
by Zacks Equity Research
Accreditation by EHNAC indicates Allscripts' (MDRX) sustainability in health data processing and transactions in terms of industry-established standards and HIPAA regulations.
Allscripts Gains From Strong Results in Q2, Competition Rife
by Zacks Equity Research
Allscripts (MDRX) continues to gain from solid Q2 results and EHR developments; a competitive industry is a concern.
McKesson (MCK) Beats on Q1 Earnings, Reiterates '19 View
by Zacks Equity Research
Strong prospects in Medical-Surgical business drove McKesson's (MCK) Q1. However, the company witnesses solid regulatory hurdles in the McKesson Canada business.
McKesson's (MCK) Q1 Earnings Beat Estimates, Sales Improve Y/Y
by Zacks Equity Research
McKesson???s Q1 results were driven by solid performance in Medical-Surgical Solutions segment.
McKesson (MCK) Q1 Earnings Top Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 0.35% and -0.82%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Earnings Lineup for Jul 26: BAX, EW & More
by Zacks Equity Research
Streak of regulatory developments and deep R&D focus are likely to drive the Medical Product industry this earnings season. Here we take a quick look at four Medical Product majors that are going to release earnings results.
Will 5 Elements Drive Quest Diagnostics (DGX) Q2 Earnings?
by Zacks Equity Research
Per Quest Diagnostics (DGX), growing strength of partnerships with health care leaders and strategic acquisitions are creating growth prospects for the top and bottom-line growth.
Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?
by Zacks Equity Research
According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.